Abstract

Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans

Poetsch, J. H. Dahlke, C. Zinser, M. E. Kasonta, R. Lunemann, S. Rechtien, A. Ly, M. L. Stubbe, H. C. Krahling, V. Biedenkopf, N. Eickmann, M. Fehling, S. K. Olearo, F. Strecker, T. Sharma, P. Lang, K. S. Lohse, A. W. Schmiedel, S. Becker, S. V. SV-Ebola Consortium Addo, M. M.
J Infect Dis. 2019; 219556-561

Permanent descriptor

https://doi.org/10.1093/infdis/jiy565

In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.